2023 - Research.com Medicine in United States Leader Award
2022 - Research.com Best Scientist Award
2005 - Distinguished Scientist Award, American Heart Association
1995 - Member of the National Academy of Medicine (NAM)
Member of the Association of American Physicians
His main research concerns Internal medicine, Endocrinology, Cholesterol, Diabetes mellitus and Obesity. His Internal medicine research is multidisciplinary, incorporating elements of Type 2 diabetes and Cardiology. His study explores the link between Cholesterol and topics such as Myocardial infarction that cross with problems in Atorvastatin, Randomized controlled trial and Coronary heart disease.
His work in Metabolic syndrome addresses issues such as Disease, which are connected to fields such as Bioinformatics and Gerontology. His Risk factor study incorporates themes from Epidemiology, Coronary artery disease, National Cholesterol Education Program, Intensive care medicine and Risk assessment. His studies deal with areas such as Physical therapy, Blood cholesterol and Therapeutic Lifestyle Changes as well as National Cholesterol Education Program.
His primary scientific interests are in Internal medicine, Endocrinology, Cholesterol, Lipoprotein and Diabetes mellitus. His studies link Cardiology with Internal medicine. He combines subjects such as Framingham Risk Score and Atorvastatin with his study of Cardiology.
His Cholesterol research is multidisciplinary, incorporating perspectives in Coronary heart disease, Excretion and Metabolism. The study incorporates disciplines such as Disease and Risk factor in addition to Diabetes mellitus. A large part of his Metabolic syndrome studies is devoted to National Cholesterol Education Program.
Scott M. Grundy focuses on Internal medicine, Endocrinology, Metabolic syndrome, Cholesterol and Cardiology. His Internal medicine study combines topics in areas such as Diabetes mellitus and Type 2 diabetes. His study looks at the relationship between Endocrinology and topics such as Risk factor, which overlap with Vascular disease.
His Metabolic syndrome research incorporates elements of Dyslipidemia, Disease, Atorvastatin, Pharmacology and Incidence. Within one scientific family, Scott M. Grundy focuses on topics pertaining to Atherosclerotic cardiovascular disease under Cholesterol, and may sometimes address concerns connected to Physical therapy. As part of one scientific family, Scott M. Grundy deals mainly with the area of Cardiology, narrowing it down to issues related to the Guideline, and often Intensive care medicine.
Internal medicine, Endocrinology, Obesity, Diabetes mellitus and Metabolic syndrome are his primary areas of study. His study on Internal medicine is mostly dedicated to connecting different topics, such as Cardiology. As a part of the same scientific family, Scott M. Grundy mostly works in the field of Endocrinology, focusing on Risk factor and, on occasion, Vascular disease and Gerontology.
The various areas that Scott M. Grundy examines in his Obesity study include Body mass index, Genetics and C-reactive protein. His Diabetes mellitus course of study focuses on Heart disease and Biomarker, Medical laboratory and Clinical biochemistry. His Metabolic syndrome research is multidisciplinary, relying on both Dyslipidemia and Incidence.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Scott M. Grundy;David Bilheimer;Alan Chait;Luther T. Clark.
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Scott M. Grundy;Diane Becker;Luther T. Clark;Richard S. Cooper.
Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity
K. G M M Alberti;Robert H. Eckel;Scott M Grundy;Paul Z. Zimmet.
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Scott M. Grundy;James I. Cleeman;C. Noel Bairey Merz;H. Bryan Brewer.
The metabolic syndrome
Robert H. Eckel;Kgmm G M M Alberti;Scott M. Grundy;Paul Z. Zimmet.
The Lancet (2005)
Definition of Metabolic Syndrome Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition
Scott M. Grundy;H. Bryan Brewer;James I. Cleeman;Sidney C. Smith.
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
John C. LaRosa;Scott M Grundy;David D. Waters;Charles Shear.
The New England Journal of Medicine (2005)
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II.
Morteza Naghavi;Peter Libby;Erling Falk;S. Ward Casscells;S. Ward Casscells.
Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity
Jeffrey D. Browning;Lidia S. Szczepaniak;Robert Dobbins;Pamela Nuremberg.
Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: Executive summary
F. X. Pi-Sunyer;D. M. Becker;C. Bouchard;R. A. Carleton.
The American Journal of Clinical Nutrition (1998)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: